Skip to content

Study · In vitro (cells) · 2020

1 result

C3a receptor blockade protects podocytes from injury in diabetic nephropathy.

Morigi M, Perico L, Corna D, Locatelli M, Cassis P, Carminati CE, Bolognini S, Zoja C, Remuzzi G, Benigni A, Buelli S

JCI insight12 Mar 2020Cited by 64 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In cultured podocytes, SS‑31 inhibited podocyte motility induced by C3a.

    In plain wordsIn cultured kidney cells, SS‑31 blocked the increased cell movement caused by C3a.

    Outcome
    DecreaseC3a-induced podocyte motility
    Study

    n: not reported in source

    cultured podocytes
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Notably, C3a-induced podocyte motility was inhibited by SS-31, a peptide with mitochondrial protective effects.
    1 context sentence
    Summary · context
    In cultured podocytes, C3a induced cAMP-dependent mitochondrial fragmentation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.